---
title: "Biggest stock movers Monday: VALN, KDP, crypto stocks, and more"
description: "Stock futures dipped as Wall Street began the last trading week of August, with attention on Nvidia's earnings. Notable stock movers included scPharmaceuticals (SCPH), which rose 13% following MannKin"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254465903.md"
published_at: "2025-08-25T13:44:43.000Z"
---

# Biggest stock movers Monday: VALN, KDP, crypto stocks, and more

> Stock futures dipped as Wall Street began the last trading week of August, with attention on Nvidia's earnings. Notable stock movers included scPharmaceuticals (SCPH), which rose 13% following MannKind's (MNKD) acquisition agreement valued at up to $360 million.

Stock futures edged lower on Monday as Wall Street kicked off the final trading week of August with focus on Nvidia’s upcoming earnings. Here are some of Monday's biggest stock movers: Biggest stock gainers scPharmaceuticals (SCPH) +13% - Shares surged after MannKind (MNKD) agreed to acquire the company in a deal valued at up to $360M. MNKD will pa...

### Related Stocks

- [SCPH.US - Scpharmaceuticals](https://longbridge.com/en/quote/SCPH.US.md)
- [MNKD.US - Mannkind](https://longbridge.com/en/quote/MNKD.US.md)
- [NVDA.US - NVIDIA](https://longbridge.com/en/quote/NVDA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 2026 年精選股票：曼恩凱德生物醫療公司 | MannKind Corp. (MNKD) 被認為是 2026 年的首選股票，原因在於其在 2025 年的進展，特別是其可吸入胰島素產品 Afrezza。該公司已向 FDA 提交申請，計劃擴大標籤以包括兒童患者，這可能增強市場潛力。此外，M | [Link](https://longbridge.com/en/news/275985463.md) |
| FDA 正在審查 Afrezza 吸入胰島素是否可以用於兒童和青少年 | 美國食品藥品監督管理局（FDA）已接受 MannKind Corporation 提交的 Afrezza 吸入粉末的補充生物製劑許可申請（sBLA），該藥物適用於 1 型或 2 型糖尿病的兒童和青少年，預計將在 2026 年 5 月 29  | [Link](https://longbridge.com/en/news/275305828.md) |
| 2026 年 FDA 對 Afrezza 和 FUROSCIX 在曼恩凱德生物醫療（MNKD）的決策如何改變了其投資故事 | MannKind Corporation 已概述了關鍵的監管里程碑，包括預計在 2026 年對 Afrezza 和 FUROSCIX 的 FDA 決策。審查時間表的一致性可能會影響投資者對 MannKind 產品組合和收入潛力的看法。FDA | [Link](https://longbridge.com/en/news/272157412.md) |
| 斯圖爾特·A·特羅斯，首席人力與工作場所官員，報告出售曼恩凱德生物醫療公司的普通股 | 曼恩凱德生物醫療的首席人事與工作場所官 Stuart A. Tross 已報告出售該公司的普通股。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供信息參考，不應被視為財務或法律建議。曼恩凱德生物醫療對 2026 年 1 月 9 | [Link](https://longbridge.com/en/news/272136429.md) |
| 曼恩凱德生物醫療公佈創紀錄的第四季度收入，並強調 2026 年的增長驅動因素 | MannKind Corporation 報告稱第四季度收入創紀錄，超過 1 億美元，並強調收購 scPharmaceuticals 是一個關鍵的增長里程碑。對於 2026 年，公司預計將有顯著的增長動力，包括兩款產品的推出以及 FDA 對 | [Link](https://longbridge.com/en/news/271937147.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.